ENTA FY 2017 Earnings Report — Enanta Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

Enanta Pharmaceuticals, Inc.ENTA

FY 2017 Earnings

Reported December 11, 2017

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2017	Prior Q	FY 2016	QoQ Change	YoY Change
Revenue	$103M	—	$88M	—	16.5%
Op. Income	$25M	—	$31M	—	-20.2%
Gross Margin	100.0%	—	100.0%	—	0.0pp
Net Margin	17.2%	—	24.5%	—	-7.3pp
EPS (Diluted)	$0.91	—	$1.13	—	-19.5%
Free Cash Flow	$50M	—	$31M	—	61.4%

Revenue Flow

Item	Amount
REVENUE	$103M
Cost of Revenue	$0
GROSS PROFIT	$103M
R&D Expenses	$57M
Selling & Marketing	$0
General & Administrative	$21M
SG&A Expenses	$21M
Other Expenses	$0
Operating Expenses	$78M
Cost & Expenses	$78M
OPERATING INCOME	$25M
Interest Income	$3M
Interest Expense	$40.0K
Other Income/Expenses	$2M
INCOME BEFORE TAX	$27M
Income Tax Expense	$9M
Net Income from Continuing Ops	$18M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$18M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$18M
D&A	$2M
EBIT	$25M
EBITDA	$27M
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$103M
Cost of Revenue	$0
GROSS PROFIT	$103M
R&D Expenses	$57M
Selling & Marketing	$0
General & Administrative	$21M
SG&A Expenses	$21M
Other Expenses	$0
Operating Expenses	$78M
Cost & Expenses	$78M
OPERATING INCOME	$25M
Interest Income	$3M
Interest Expense	$40.0K
Other Income/Expenses	$2M
INCOME BEFORE TAX	$27M
Income Tax Expense	$9M
Net Income from Continuing Ops	$18M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$18M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$18M
D&A	$2M
EBIT	$25M
EBITDA	$27M
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$18M
Depreciation & Amortization	$2M
Stock-Based Compensation	$13M
Deferred Income Tax	-$2M
Other Non-Cash Items	-$581.0K
Change in Working Capital	$22M
OPERATING CASH FLOW	$53M
Capital Expenditure	-$3M
Acquisitions (Net)	$0
Purchases of Investments	-$251M
Sales/Maturities of Investments	$249M
Other Investing Activities	-$2M
NET CASH FROM INVESTING	-$5M
Net Debt Issuance	-$73.0K
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$1M
NET CASH FROM FINANCING	$1M
FREE CASH FLOW	$50M
Net Change in Cash	$49M

Balance Sheet

Item	Amount
Cash & Equivalents	$66M
Short-Term Investments	$158M
Net Receivables	$11M
Inventory	$0
Other Current Assets	$4M
TOTAL CURRENT ASSETS	$238M
PP&E (Net)	$8M
Goodwill	$0
Intangible Assets	$0
Long-Term Investments	$70M
Tax Assets	$10M
Other Non-Current Assets	$608.0K
TOTAL NON-CURRENT ASSETS	$89M
TOTAL ASSETS	$327M
Account Payables	$4M
Short-Term Debt	$0
Deferred Revenue	$9M
Other Current Liabilities	$9M
TOTAL CURRENT LIABILITIES	$21M
Long-Term Debt	$0
Deferred Revenue NC	$15.0K
Deferred Tax Liabilities	$1M
Other Non-Current Liabilities	$4M
TOTAL NON-CURRENT LIABILITIES	$4M
TOTAL LIABILITIES	$25M
Common Stock	$191.0K
Additional Paid-In Capital	$256M
Retained Earnings	$45M
Treasury Stock	$0
Accum. Other Comp. Income	-$112.0K
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$302M
Minority Interest	$0
TOTAL EQUITY	$302M
TOTAL LIABILITIES & EQUITY	$327M
Total Debt	$458.0K
Net Debt	-$65M